Montelair 10 Mg Film-Coated Tablets (Montelukast)

Montelukast, the active ingredient in Montelair 10 Mg Film-Coated Tablets, is a leukotriene receptor antagonist presented as a 10 mg film-coated tablet for oral use. It treats asthma and allergic rhinitis, and is used in patients requiring prophylaxis or chronic management.

GNH USA supplies Montelair 10 Mg Film-Coated Tablets as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to control airway inflammation and allergic symptoms. - Asthma: provides prophylaxis and chronic treatment to reduce exacerbations and improve control. - Exercise‑induced bronchoconstriction: prevents airway narrowing that occurs during physical activity. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching associated with seasonal or perennial allergies.

Common side effects are generally mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Abdominal pain: occasional discomfort. - Cough: non‑productive. - Sore throat: mild irritation. - Nasal congestion: mild blockage. - Diarrhoea: loose stools.

Serious or Rare Side Effects: - Allergic reactions: rash, angioedema, or anaphylaxis. - Neuropsychiatric events: mood changes, depression, or suicidal thoughts. - Hepatic enzyme elevation: potential liver function abnormalities. - Stevens‑Johnson syndrome: severe skin reactions. - Severe bronchospasm: paradoxical worsening of breathing.

Montelair should be used with awareness of specific safety considerations. - Assess asthma control: ensure baseline control before initiating therapy. - Monitor neuropsychiatric signs: watch for mood changes or depression. - Use cautiously in hepatic impairment: dose adjustment may be needed. - Not for acute asthma attacks: do not replace rescue inhalers. - Review concomitant medications: consider potential interactions. - Store at below 25°C: keep in the original pack, protect from moisture.

Montelair can interact with several drug classes, requiring attention to avoid reduced efficacy or increased risk.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, phenytoin, carbamazepine): may markedly lower montelukast plasma levels. - Phenobarbital: can reduce therapeutic effect.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs, SNRIs): may increase risk of neuropsychiatric events. - Azole antifungals (ketoconazole, itraconazole): can raise montelukast concentrations. - Beta‑agonists: additive bronchodilatory effect may require dose adjustment.